Results 111 to 120 of about 26,436 (212)

Effects of three flavonoids on the metabolism of lenvatinib [PDF]

Lenvatinib is a first-line therapy for the treatment of hepatocellular carcinoma (HCC), an active multi-target tyrosine kinase inhibitor (TKI). The interaction between Traditional Chinese Medicine (TCM) and chemicals has increasingly become a research ...
Ren-ai Xu, Jinzhao Yang, Jie Chen, Xiaohai Chen, Qingqing Li   +4 more
core   +1 more source

Clinicogenomic Features and Outcomes of Adenoid Cystic Carcinoma With Central Nervous System Metastases: A Single‐Institution Cohort Study

Head &Neck, Volume 48, Issue 11, Page 3193-3201, November 2026.
ABSTRACT Background Adenoid cystic carcinoma (ACC) is a rare malignancy with a propensity for perineural invasion and hematogenous spread. Central nervous system (CNS) involvement is uncommon, and detailed clinical and genomic data on this aspect of the disease remain limited.
Omar Elghawy, Jack Stylli, Martin Kurian, Eitan Halper‐Stromberg, Aditi Singh, Christopher D'Avella, Lee Hartner, Roger B. Cohen   +7 more
wiley   +1 more source

RARRES1 inhibits hepatocellular carcinoma progression and increases its sensitivity to lenvatinib through interaction with SPINK2

Biology Direct
Background Lenvatinib is an oral small molecule inhibitor approved for treating patients with unresectable hepatocellular carcinoma (HCC) worldwide. Increasing cell sensitivity to lenvatinib would be an effective method of improving therapeutic efficacy.
Yarong Guo, Bao Chai, Hezhao Zhang, Xinhao Chai, Yan Chen, Jun Xu, Liwei Qin, Yuting Chai   +7 more
doaj   +1 more source

Lenvatinib-Induced Acalculous Cholecystitis—An Often-Unrecognized Toxicity: A Case Series and Literature Review

Current Oncology
Lenvatinib is an oral multi-kinase inhibitor which is used for the treatment of renal cell carcinoma, non-iodine avid differentiated thyroid cancer, hepatocellular carcinoma, and endometrial cancer.
Christos Cortas, Chloe Symeonidou, Haris Charalambous   +2 more
doaj   +1 more source

GPX2 inhibition enhances antitumor efficacy of lenvatinib via promoting immunogenic cell death in hepatocellular carcinoma

Journal of Translational Medicine
Background Immunogenic cell death (ICD) is a distinct subtype of regulatory cell death, and represents a potential mechanism to remodel the tumor microenvironment. Lenvatinib is established as the first-line therapy for advanced hepatocellular carcinoma (
Yingzheng Tan, Lei Yang, Tao Xu, Qingbin Wang, Meiyuan Huang, Zhijian Zhao, Xun Chen, Caixi Tang, Wenliang Tan   +8 more
doaj   +1 more source

Efficacy of TACE Combined with Lenvatinib Plus Sintilimab for Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava and/or Right Atrium

, 2023
Shangkun Ning,1,* Xinge Li,2,* Xiangyu Ma,1 Jibing Liu,1 Xu Chang3 1Department of Interventional Therapy I, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong ...
Li X, Ning S, Liu J, Ma X, Chang X
core  

Efficacy and Safety of Benmelstobart Plus Anlotinib in Advanced Endometrial Cancer: Results of a Multi‐Cohort, Phase II Study (ETER200)

MedComm, Volume 7, Issue 11, November 2026.
The multi‐cohort, Phase II ETER200 study evaluated benmelstobart plus anlotinib or either agent alone in previously treated metastatic or recurrent endometrial cancer across molecular subtypes. In non–MSI‐H/pMMR tumors, benmelstobart plus anlotinib demonstrated durable antitumor activity without unexpected safety signals.
Shanhui Liang, Xiaojun Chen, Ke Wang, Dong Wang, Ruifang An, Jianqing Hou, Ying Yang, Danbo Wang, Pengpeng Qu, Bingzhong Zhang, Wei Duan, Xiumin Li, Aimin Zang, Guohua Yu, Hanmei Lou, Desheng Yao, Shuzhen Wang, Dong Yan, Liang Li, Xiaowei Liu, Weidong Zhao, Zhengzheng Chen, Jing Fei, Jundong Li, Jing Wang, Zhilian Wang, Shuzhong Yao, Fangling Ning, Huaijun Zhou, Li Sun, Lingya Pan, Qing Liu, Haihua Yang, Li Wang, Mingjun Zhang, Xiaoxiang Chen, Jianlin Yuan, Xinwen Zhang, Youzhong Zhang, Qinping Liao, Xiaohua Wu   +40 more
wiley   +1 more source

Repression of LSD1/KDM1A activity improves the response of liver cancer cells to the lenvatinib

Discover Oncology
Background/Aim Lenvatinib, a multikinase inhibitor, has become a second-line treatment option for unresectable liver cancer, while its monotherapy response rate is limited.
Yi Zong, Zhigang Tao, Siyi Jiang, Minyuan Wang, Weihua Yu   +4 more
doaj   +1 more source

Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial

Lenvatinib, a multi-kinase inhibitor, has been approved as first-line treatment for advanced hepatocellular carcinoma (HCC), but its efficacy is limited.
Dan Cui, Weiping Zhou, Haojie Jin, Yaoping Shi, Lei Xia, Donghua Shi, Zhen Sun, Jiachang Chi, Siying Wang, Wu Yang, Tao Wang, Rene Bernards, Guangxin Jin, Qi Jia, Zicheng Lv, Yan Lin, Jiaojiao Zheng, Meng Li, Shengxian Yuan, Bo Zhai, Xiaoyin Tang, Hao Feng, Fan Yang, Wenxin Qin   +23 more
core   +1 more source

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma

, 2023
Leijuan Gan,1– 3,* Mengran Lang,1– 4,* Xindi Tian,1– 3 Shaohua Ren,1– 3 Guangtao Li,1– 3 Yayue Liu,1– 3 Ruyu Han,1– 3 Kangwei Zhu,1– 3 Huikai Li,1– 3 Qiang Wu,1– 3 Yunlong Cui,1– 3 Wei Zhang,1– 3 Feng Fang,1– 3 Qiang Li,1– 3 Tianqiang Song1– 3 ...
Li G, Lang M, Li H, Han R, Wu Q, Fang F, Li Q, Zhang W, Liu Y, Gan L, Tian X, Cui Y, Zhu K, Song T, Ren S   +14 more
core